Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Claire Fraser, insider at Becton, Dickinson and

Claire Fraser Insider Information

Claire M. Fraser, Ph.D., serves as a director of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. Dr. Fraser has been a member of the board since 2016.

Dr. Fraser is the director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine in Baltimore, Maryland. From 1998 to 2007, she served as president and director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies. Dr. Fraser is the president and a director of the American Association for the Advancement of Science and also serves as a director of Ohana Biosciences Inc.

Dr. Fraser is a prominent scientist with a strong background in infectious diseases and molecular diagnostics, including the development of novel diagnostics and vaccines. She also brings considerable managerial experience in her field.

How do I contact Claire Fraser?

The corporate mailing address for Dr. Fraser and other Becton, Dickinson and executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and can also be reached via phone at (201) 847-6800. Learn More on Claire Fraser's contact information.

Has Claire Fraser been buying or selling shares of Becton, Dickinson and?

Claire Fraser has not been actively trading shares of Becton, Dickinson and during the last quarter. 0 shares of the stock in a transaction that occurred on Friday, May 20th. Learn More on Claire Fraser's trading history.

Who are Becton, Dickinson and's active insiders?

Becton, Dickinson and's insider roster includes Alexandre Conroy (EVP), Claire Fraser (Director), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Betty Larson (EVP), James Lim (EVP), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and?

During the last year, insiders at the medical instruments supplier sold shares 16 times. They sold a total of 38,586 shares worth more than $10,153,749.72. The most recent insider tranaction occured on May, 6th when EVP David Hickey sold 475 shares worth more than $121,600.00. Insiders at Becton, Dickinson and own 0.5 % of the company. Learn More about insider trades at Becton, Dickinson and.

Information on this page was last updated on 5/6/2022.

Claire Fraser Insider Trading History at Becton, Dickinson and

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2022Sell841$271.70$228,499.70View SEC Filing Icon  
8/18/2021Sell387$251.58$97,361.46View SEC Filing Icon  
5/27/2021Sell390$241.36$94,130.40View SEC Filing Icon  
2/11/2020Sell1,500$258.72$388,080.00View SEC Filing Icon  
8/7/2019Sell1,429$243.26$347,618.54View SEC Filing Icon  
See Full Table

Claire Fraser Buying and Selling Activity at Becton, Dickinson and

This chart shows Claire Fraser's buying and selling at Becton, Dickinson and by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Overview

Becton, Dickinson and logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $252.30
Low: $247.82
High: $253.47

50 Day Range

MA: $260.32
Low: $245.58
High: $275.42

2 Week Range

Now: $252.30
Low: $235.13
High: $280.62

Volume

909,746 shs

Average Volume

1,323,168 shs

Market Capitalization

$71.92 billion

P/E Ratio

39.79

Dividend Yield

1.39%

Beta

0.64
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.